Patients with metastatic colorectal cancer.
Conditions
Interventions
[Induction treatment:FOLFOXIRI+BV] Administered for a maximum of 12 cycles. BV: 5mg/kg (d.i.v.) L-OHP: 85 mg/sq.m (d.i.v.) CPT-11:165mg/sq.m (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5FU:3,200mg/sq.m (c
Sponsors
EPS Corporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Written Informed consent. 2. Histopathologically proven diagnosis of colorectal cancer (adenocarcinoma) excluding vermiform appendix cancer and proctos cancer. 3. Not resectable metastatic colorectal cancer 4. Age at enrollment is >= 20 and <= 75 years 5. ECOG PS < 2 if age < 70 years, ECOG PS = 0 if age = 71-75 years 6. One or more measurable lesion in RECIST ver.1.1 criteria according to contrast enhanced CT chest / abdomen / pelvis diagnosis. 7. Not previously treated with chemotherapy. (Previous adjuvant by fluoropyrimidine monotherapy is allowed if more than 24 weeks have elapsed between the end of adjuvant therapy and first relapse.) 8. Vital organ functions (listed below) are preserved within 2 weeks prior to entry. Data recorded nearest to the entry should be referred. Blood transfusion or erythropoiesis stimulating agents less than 2 weeks prior to the tests are not allowed. Neu. >= 1,500/cubicmillimeter Pt. >= 100,000/cubicmillimeter Hb. >= 9.0 g/dL T-bil. <= 2.0 mg/dL AST and ALT,ALP <= upper limit of normal (ULN)*2.5 (<= ULN*5 in case of liver metastasis) Serum creatinine <= upper limit of normal (ULN) *1.5 PT-INR < 1.5 Proteinuria <= 2+ 9. UGT1A1 genotype tested. Categorized into Wild or single Hetero.
Exclusion criteria
Exclusion criteria: 1. Previously treated with irradiation to bone marrow constituting 20% or more of irradiation field. 2. Untreated brain metastases or spinal cord compression or primary brain tumors. 3. History of CNS disease.[except for asymptomatic Lacunar stroke] 4. Requiring chronic systemic corticosteroid treatment. 5. Current or recent ongoing treatment with anticoagulants. 6. Clinically significant cardiovascular disease for example cerebrovascular accidents, myocardial infarction, unstable angina, congestive heart failure, serious cardiac arrhythmia requiring medication. 7. Treatment with any investigational drug within 4 weeks. 8. Patient with Uncontrolled hypertension, Uncontrolled diabetes, Uncontrolled diarrhea->=grade 1 peripheral neuropathy, Active peptic ulcer, Non-healing wound, Clinically important diseases. 9. Major surgical procedure within 28 days prior to study treatment start, open biopsy, or significant traumatic injury, or anticipation of the need for major surgical procedure. 10. Lack of physical integrity of the upper gastrointestinal tract. 11. Pregnant women, lactating woman , positive by pregnancy test , wishing to become pregnant, and Sexually active males. 12. Hepatitis B or hepatitis C . Evidence of HIV infection. 13. Previous Chemotherapy for other organs. 14. Other active co-existing malignancies. 15. History / Presence of thrombosis within 1 year requiring medication. 16. History / Presence of paralytic ileus, obstruction or gastrointestinal perforation. 17. Malignant coelomic fluid required drainage. 18. History of allergy to Chinese hamster ovary cell proteins, or any of the components of the study medications. 19. History of fluoropyrimidine severe side effects caused by DPD defect. 20. Interstitial pneumonitis or pulmonary fibrosis. 21. Evidence or requiring systemic treatment for Infectious disease. 22. Patient who is judged by the investigator to be inappropriate for study participation for any reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS) at 10 months; by investigator-reported measurements. | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate (RR) ; by investigator-reported measurements, by central review PFS; by central review Overall survival (OS) Efficacy by RAS status ; RR,PFS,OS Incidence of adverse events Time to treatment-failure Completion rate in Induction treatment Relative Dose Intensity Treatment duration | — |
Countries
Japan
Contacts
Public ContactHideki Furuya
EPS Corporation. Clinical Information Division Data Manegement 1
Outcome results
None listed